Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00044421 |
The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.
Condition | Intervention | Phase |
---|---|---|
Diabetic Neuropathies Diabetes Mellitus |
Drug: Ruboxistaurin mesylate |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | LY333531 Treatment of Peripheral Neuropathy in Patients With Diabetes |
Estimated Enrollment: | 400 |
Study Start Date: | July 2002 |
Study Completion Date: | October 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Call 1-877-CTLILLY (1977-285-4559) or 1317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Study ID Numbers: | 2784, B7A-MC-MBBR |
Study First Received: | August 28, 2002 |
Last Updated: | November 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00044421 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Metabolic Diseases Neuromuscular Diseases Diabetic Neuropathies Ruboxistaurin Peripheral Nervous System Diseases Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder Diabetes Complications |
Metabolic Diseases Diabetic Neuropathies Molecular Mechanisms of Pharmacological Action Nervous System Diseases Diabetes Mellitus Endocrine System Diseases Enzyme Inhibitors |
Pharmacologic Actions Neuromuscular Diseases Peripheral Nervous System Diseases Ruboxistaurin Glucose Metabolism Disorders Diabetes Complications |